Fertomid

Fertomid is a fertility agent used to stimulate ovulation in women who want to become pregnant.

Product dosage: 50mg
Package (num)	Per pill	Price	Buy
30	2.07 $	62.01 $ (0%)	🛒 Add to cart
60	1.75 $	124.02 $ 105.30 $ (15%)	🛒 Add to cart
90	1.64 $	186.03 $ 147.42 $ (21%)	🛒 Add to cart
120	1.59 $	248.04 $ 190.71 $ (23%)	🛒 Add to cart
180	1.54 $	372.06 $ 277.29 $ (25%)	🛒 Add to cart
270	1.51 $	558.09 $ 407.16 $ (27%)	🛒 Add to cart
360	1.49 $ Best per pill	744.12 $ 535.86 $ (28%)	🛒 Add to cart

Fertomid (clomiphene citrate) represents a first-line pharmacological intervention for anovulatory infertility. As a selective estrogen receptor modulator (SERM), it effectively stimulates follicle development and promotes ovulation in appropriately selected patients. This medication requires precise medical supervision to optimize therapeutic outcomes while minimizing risks. The following comprehensive product information details essential clinical parameters for healthcare providers managing ovulatory dysfunction.

Features

• Contains clomiphene citrate as the active pharmaceutical ingredient
• Available in 50 mg tablet formulation
• Selective estrogen receptor modulator (SERM) mechanism of action
• Oral administration with high bioavailability
• Standardized manufacturing under GMP conditions
• Precisely calibrated dosage strength for titration

Benefits

• Effectively induces ovulation in approximately 80% of appropriately selected anovulatory women
• Restores regular menstrual cycles in patients with ovulatory dysfunction
• Non-invasive oral administration compared to injectable alternatives
• Established safety profile with decades of clinical use
• Cost-effective first-line treatment option
• Enables timed intercourse and fertility awareness

Common use

Fertomid is primarily indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. It is particularly effective in patients with polycystic ovary syndrome (PCOS) who have demonstrated estrogenic activity. The medication works by blocking estrogen receptors at the hypothalamus, which increases gonadotropin-releasing hormone (GnRH) pulsatility, subsequently elevating follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels from the pituitary gland. This hormonal cascade stimulates follicular development and maturation, ultimately leading to ovulation. Treatment is typically initiated in women who have undergone complete infertility evaluation, including assessment of tubal patency and semen analysis of the partner.

Dosage and direction

The recommended initial dosage is 50 mg (one tablet) daily for five days, beginning on the fifth day of the menstrual cycle. Treatment may be started at any time in patients with amenorrhea. If ovulation does not occur, the dosage may be increased to 100 mg daily for five days in the subsequent cycle. This dosage escalation should only occur under medical supervision. The maximum recommended daily dosage is 150 mg. Treatment beyond three cycles is not generally recommended if ovulation occurs but conception doesn’t follow. Ultrasound monitoring of follicular development is advised, especially during the first treatment cycle or when increasing dosage. Coitus should be timed to occur every other day beginning five days after the last dose until ovulation is confirmed.

Precautions

Patients should undergo thorough gynecological examination before treatment initiation to exclude uterine pathology, ovarian cysts, or other pelvic abnormalities. Liver function should be assessed as clomiphene is metabolized hepatically. Visual symptoms should be promptly reported as they may indicate serious complications. Multiple pregnancy occurs in approximately 8% of clomiphene-conceived pregnancies, predominantly twins. Ovarian hyperstimulation syndrome (OHSS) may occur, particularly in patients with polycystic ovaries. Long-term use (超过 12 cycles) may slightly increase the risk of borderline ovarian tumors. Thyroid and adrenal disorders should be ruled out before treatment. Patients should be advised that the incidence of congenital malformations may be slightly increased with clomiphene therapy.

Contraindications

Fertomid is contraindicated in patients with: pregnancy; liver disease or history of hepatic dysfunction; abnormal uterine bleeding of undetermined origin; ovarian cysts not associated with polycystic ovarian syndrome; uncontrolled thyroid or adrenal dysfunction; organic intracranial lesions such as pituitary tumors; hypersensitivity to clomiphene citrate or any component of the formulation. The medication should not be used in patients with estrogen-dependent neoplasms. It is contraindicated in cases where the male partner’s infertility has not been properly evaluated.

Possible side effects

Common adverse reactions include vasomotor flushes (10-20%), abdominal discomfort (5-10%), ovarian enlargement (5-10%), breast tenderness (2-5%), and visual disturbances (1-2%). Less frequently reported effects include nausea, vomiting, nervousness, insomnia, headache, dizziness, lightheadedness, hair loss, and weight gain. Serious but rare side effects include ovarian hyperstimulation syndrome, blurred vision or other visual symptoms, and ovarian torsion. Most side effects are dose-related and reversible upon discontinuation of therapy. Patients should be monitored for mood changes as depression has been reported.

Drug interaction

Clomiphene may alter the metabolism of medications including anticoagulants (may potentiate effects), thyroxine (may increase requirement), and dopamine antagonists (may diminish prolactin-reducing effects). Concomitant use with other fertility medications such as gonadotropins may increase the risk of ovarian hyperstimulation. Herbal supplements with estrogenic properties may interfere with Fertomid’s mechanism of action. Corticosteroids may enhance ovulation induction effects in some patients with adrenal hyperplasia. Always review the patient’s complete medication profile before prescribing.

Missed dose

If a dose is missed, the patient should take it as soon as remembered unless it is almost time for the next dose. Doubling the dose to make up for a missed dose is not recommended. The five-day course should be completed as prescribed for optimal follicular development. If multiple doses are missed, the healthcare provider should be consulted about whether to continue or restart the cycle. Consistent timing of administration helps maintain stable drug levels.

Overdose

Symptoms of overdose may include nausea, vomiting, vasomotor flushes, abdominal pain, ovarian enlargement, and visual disturbances. There is no specific antidote for clomiphene overdose. Treatment should be symptomatic and supportive. Gastric lavage may be considered if ingestion was recent. Medical supervision is essential, particularly regarding ovarian size and function. Dialysis is not likely to be effective due to high protein binding. Patients should be monitored for potential ovarian hyperstimulation syndrome.

Storage

Store at controlled room temperature (20-25°C or 68-77°F). Protect from light and moisture. Keep in the original container with the lid tightly closed. Do not store in bathroom cabinets where humidity levels fluctuate. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Proper disposal of unused medication is recommended through medication take-back programs.

Disclaimer

This information is intended for medical professionals and should not replace comprehensive clinical judgment. Treatment with Fertomid must be initiated and monitored by qualified healthcare providers experienced in fertility management. Individual patient response may vary, and therapeutic decisions should be based on complete medical evaluation. The manufacturer is not liable for improper use or dosage miscalculations. Always refer to the latest prescribing information and clinical guidelines.

Reviews

Clinical studies demonstrate ovulation rates of approximately 70-80% in appropriately selected patients, with pregnancy rates of 30-40% per ovulatory cycle. Meta-analyses confirm clomiphene citrate’s efficacy as first-line treatment for anovulatory infertility. Many reproductive endocrinologists note its established safety profile when properly monitored. Some studies suggest slightly higher multiple pregnancy rates compared to natural conception. Patient satisfaction surveys indicate appreciation for oral administration versus injectable alternatives, though some report side effects as challenging. Long-term follow-up studies show no significant increase in major congenital malformations when used as directed.